S. Percy Ivy

Associate Chief

National Cancer Institute

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. S. Percy Ivy is an Associate Chief at the National Cancer Institute in the United States. His research focuses on oncology drug development, precision oncology clinical trials, and the biological variability of tumor biomarkers. He has contributed to numerous studies, including those on the efficacy of targeted therapies and the outcomes of cancer treatments during pregnancy.

Articles (9)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Collaborators (7)

John Christopher Brady

Duke University

UNITED STATES

View details

Joanne Kwak-Kim

Rosalind Franklin University of Medicine and Science

UNITED STATES

View details

Dai Chihara

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Heather H. Cheng

University of Washington

UNITED STATES

View details

Andrea Denicoff

Head, NCTN Clinical Trials Operations

National Cancer Institute

UNITED STATES

View details

Natalie Cook

The University of Manchester

UNITED KINGDOM

View details

Thomas D. Nolin

University of Pittsburgh School of Pharmacy

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

S. Percy Ivy

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants

Accelerating the Future of Oncology Drug Development

Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients

Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors

Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute

Implementing Modernized Eligibility Criteria in US National Cancer Institute Clinical Trials

Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute

Collaborators (7)

John Christopher Brady

Joanne Kwak-Kim

Dai Chihara

Heather H. Cheng

Andrea Denicoff

Natalie Cook

Thomas D. Nolin

Make your next move.